SAN RAFAEL, Calif.,
Oct. 7, 2019 /PRNewswire/ -- BioMarin
Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of
Lon Cardon, Ph.D. to Chief
Scientific Strategy Officer, a newly created role to enrich
BioMarin's pipeline, which drives the future growth of the company.
Dr. Cardon's promotion to lead BioMarin's scientific strategy is
effective immediately.
"We are thrilled to promote Lon into the leadership role for our
scientific strategy at BioMarin. BioMarin is committed to
pioneering breakthrough science that has the potential to make a
big impact on rare patient populations. Lon will support our
company's growth by identifying the right balance of resources
within BioMarin to move the most promising molecules through our
pipeline," said Jean-Jacques Bienaimé, Chairman and Chief Executive
Officer. "Lon has done an outstanding job of building our research
capabilities positioning BioMarin for future success and brings his
knowledge in genetics and drug discovery generally, and
specifically in BioMarin's scientific expertise to this role."
In this newly created leadership position, Dr. Cardon's
responsibilities expand beyond the Research functions at BioMarin
and now include oversight of the company's product portfolio. He
will lead cross functional activities to build our leadership
position in precision medicine in support of patients with rare
genetic diseases and drive long-term growth through the oversight
of an exceptional pipeline of first- or best-in-class
therapies.
"I have worked closely with Lon over the past two years and have
the utmost confidence in his abilities to oversee a critical part
of our business that drives our future growth," said Hank Fuchs, M.D., President, Worldwide Research
and Development. "He is uniquely qualified to champion science at
BioMarin that has the potential to change the practice of medicine
and to bring together cross functional teams that will deliver
potentially life-changing medicine to patients with rare
diseases."
Previously, Dr. Cardon was Senior Vice President of Alternative
Discovery and Development, and Head of Target Sciences at
GlaxoSmithKline plc (GSK). During his nine years at GSK, he led
platform groups in genetics, statistics, bioinformatics,
epidemiology and clinical pharmacology and created a new division
for exploratory therapeutic areas and platforms, including rare
diseases, gene therapy, ophthalmology, women's health and others.
Dr. Cardon was a longstanding member of GSK's R&D executive
team, ultimately chairing their discovery board which governed the
scientific direction of all of GSK's preclinical to phase 2
programs.
Before moving into the industry, Dr. Cardon was a professor
of Biostatistics at the University of
Washington and full member of the Fred Hutchinson Cancer
Research Centre. Prior to that he was a professor and Wellcome
Trust Principal Fellow at the University of
Oxford. He received his PhD from the University of Colorado, Boulder and did his
postdoctoral training at Stanford
University. He is an elected Fellow of the UK's Academy of
Medical Sciences and the American Association for the Advancement
of Science.
About BioMarin
BioMarin is a global biotechnology company that develops and
commercializes innovative therapies for patients with serious and
life-threatening rare genetic diseases. The company's portfolio
consists of seven commercialized products and multiple clinical and
pre-clinical product candidates. For additional information, please
visit www.biomarin.com. Information on such website is not
incorporated by reference into this press release.
BioMarin® is a registered trademarks of BioMarin Pharmaceutical
Inc.
Contacts:
|
|
|
|
Investors
|
Media
|
Traci
McCarty
|
Debra
Charlesworth
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
(415)
455-7558
|
(415)
455-7451
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biomarin-promotes-lon-cardon-phd-to-chief-scientific-strategy-officer-300932760.html
SOURCE BioMarin Pharmaceutical Inc.